Scarica l'app Stockscreener
1.85
0.54%
-0.00
Dopo l'orario di chiusura:
1.84
-0.01
-0.54%
Precedente Chiudi:
$1.85
Aprire:
$1.86
Volume 24 ore:
268.14K
Relative Volume:
0.64
Capitalizzazione di mercato:
$149.03M
Reddito:
$7.05M
Utile/perdita netta:
$-30.43M
Rapporto P/E:
-4.8838
EPS:
-0.3788
Flusso di cassa netto:
$21.84M
1 W Prestazione:
-9.80%
1M Prestazione:
-17.86%
6M Prestazione:
-0.54%
1 anno Prestazione:
-10.24%
Intervallo 1D:
$1.82
$1.87
Intervallo di 1 settimana:
$1.78
$2.055
Portata 52W:
$1.61
$4.62
Proqr Therapeutics N V Stock (PRQR) Company Profile
Nome
Proqr Therapeutics N V
Settore
Industria
Telefono
-
Indirizzo
-
Confronta PRQR con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PRQR
Proqr Therapeutics N V
|
1.85 | 149.03M | 7.05M | -30.43M | 21.84M | -0.3788 |
|
VRTX
Vertex Pharmaceuticals Inc
|
495.42 | 125.50B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
689.50 | 75.31B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
591.45 | 35.72B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
242.43 | 31.39B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
249.84 | 26.27B | 3.32B | -860.46M | -1.04B | -8.32 |
Proqr Therapeutics N V Stock (PRQR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-03-10 | Aggiornamento | Citigroup | Neutral → Buy |
| 2025-01-10 | Iniziato | Oppenheimer | Outperform |
| 2024-10-29 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2023-11-08 | Aggiornamento | Chardan Capital Markets | Neutral → Buy |
| 2023-03-30 | Aggiornamento | JMP Securities | Mkt Perform → Mkt Outperform |
| 2022-12-22 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2022-02-14 | Downgrade | Citigroup | Buy → Neutral |
| 2022-02-11 | Downgrade | Raymond James | Strong Buy → Mkt Perform |
| 2022-02-11 | Downgrade | Stifel | Buy → Hold |
| 2022-02-01 | Iniziato | Raymond James | Strong Buy |
| 2021-05-03 | Iniziato | Stifel | Buy |
| 2021-03-25 | Reiterato | Citigroup | Buy |
| 2020-11-03 | Ripresa | Cantor Fitzgerald | Overweight |
| 2019-03-12 | Reiterato | Chardan Capital Markets | Buy |
| 2018-12-19 | Iniziato | RBC Capital Mkts | Outperform |
| 2018-11-15 | Iniziato | Citigroup | Buy |
| 2018-09-19 | Iniziato | Evercore ISI | Outperform |
| 2017-09-26 | Reiterato | JMP Securities | Mkt Outperform |
| 2016-06-20 | Iniziato | Chardan Capital Markets | Neutral |
| 2014-10-15 | Iniziato | Deutsche Bank | Buy |
| 2014-10-13 | Iniziato | H.C. Wainwright | Buy |
Mostra tutto
Proqr Therapeutics N V Borsa (PRQR) Ultime notizie
ProQR Therapeutics (NASDAQ:PRQR) Rating Increased to Buy at Citigroup - Defense World
ProQR Therapeutics upgraded by Citigroup with a new price target - Quantisnow
ProQR Therapeutics (NASDAQ:PRQR) Stock Rating Upgraded by Citigroup - MarketBeat
ProQR Therapeutics (NASDAQ:PRQR) Upgraded by Citigroup to Buy Rating - MarketBeat
Citigroup Upgrades ProQR Therapeutics to Buy From Neutral, Price Target is $4 -March 10, 2025 at 07:33 am EDT - Marketscreener.com
Citi raises ProQR stock rating to buy, sets $4 target By Investing.com - Investing.com Australia
Citi raises ProQR stock rating to buy, sets $4 target - Investing.com India
ProQR Therapeutics (PRQR) to Release Earnings on Wednesday - MarketBeat
ProQR Therapeutics (NASDAQ:PRQR) Shares Cross Below Two Hundred Day Moving AverageShould You Sell? - MarketBeat
ProQR Therapeutics (PRQR) Expected to Announce Earnings on Wednesday - Defense World
ProQR Therapeutics (NASDAQ:PRQR) Receives Average Recommendation of "Buy" from Brokerages - MarketBeat
ProQR Therapeutics (NASDAQ:PRQR) Receives Average Recommendation of “Buy” from Brokerages - Defense World
ProQR Therapeutics (NASDAQ:PRQR) Stock Price Passes Above 50-Day Moving AverageHere's What Happened - MarketBeat
ProQR Therapeutics N.V.'s (NASDAQ:PRQR) market cap touched US$250m last week, benefiting both individual investors who own 59% as well as institutions - Simply Wall St
Analyzing ProQR Therapeutics (NASDAQ:PRQR) & Avadel Pharmaceuticals (NASDAQ:AVDL) - Defense World
Head to Head Contrast: ProQR Therapeutics (NASDAQ:PRQR) versus Anebulo Pharmaceuticals (NASDAQ:ANEB) - Defense World
Jones Trading sets ProQR stock Buy rating, $11 price target - MSN
This Ralph Lauren Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
Jones Trading Initiates Coverage of ProQR Therapeutics N.V. (PRQR) with Buy Recommendation - Nasdaq
Jones Trading sets ProQR stock Buy rating, $11 price target By Investing.com - Investing.com Australia
ProQR Therapeutics N.V.'s (NASDAQ:PRQR) largest shareholders are individual investors with 60% ownership, institutions own 17% - Yahoo Finance
ProQR Therapeutics (NASDAQ:PRQR) Receives Average Rating of "Buy" from Analysts - MarketBeat
ProQR Therapeutics (NASDAQ:PRQR) Given Average Recommendation of “Buy” by Brokerages - Defense World
Ballentine Partners LLC Takes Position in ProQR Therapeutics (NASDAQ:PRQR) - Defense World
Analysts Offer Predictions for PRQR FY2025 Earnings - Defense World
Cantor Fitzgerald Weighs in on PRQR FY2025 Earnings - MarketBeat
ProQR Therapeutics (NASDAQ:PRQR) Short Interest Update - MarketBeat
ProQR Therapeutics' SWOT analysis: RNA editing firm's stock poised for growth - Investing.com
Oppenheimer Initiates Coverage on ProQR Therapeutics (NASDAQ:PRQR) - Defense World
ProQR Therapeutics (NASDAQ:PRQR) Receives $7.60 Consensus Target Price from Analysts - Defense World
ProQR Therapeutics (NASDAQ:PRQR) Given Average Rating of "Buy" by Analysts - MarketBeat
BNP Paribas Financial Markets Increases Position in ProQR Therapeutics (NASDAQ:PRQR) - Defense World
ProQR Therapeutics' SWOT analysis: RNA-editing stock poised for clinical leap - Investing.com
ProQR Therapeutics’ (PRQR) “Market Outperform” Rating Reiterated at JMP Securities - Defense World
ProQR Therapeutics’ (PRQR) Buy Rating Reiterated at HC Wainwright - Defense World
ProQR Therapeutics (NASDAQ:PRQR shareholders incur further losses as stock declines 21% this week, taking five-year losses to 70% - Simply Wall St
Proqr Therapeutics N V Azioni (PRQR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.98%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):